Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Applied Health Economics and Health Policy
Erschienen in: Applied Health Economics and Health Policy 3/2014

01.06.2014 | Review Article

Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods

verfasst von: P. Watson, L. Preston, H. Squires, J. Chilcott, A. Brennan

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Our objective was to review modelling methods for type 2 diabetes mellitus prevention cost-effectiveness studies. The review was conducted to inform the design of a policy analysis model capable of assisting resource allocation decisions across a spectrum of prevention strategies. We identified recent systematic reviews of economic evaluations in diabetes prevention and management of obesity. We extracted studies from two existing systematic reviews of economic evaluations for the prevention of diabetes. We extracted studies evaluating interventions in a non-diabetic population with type 2 diabetes as a modelled outcome, from two systematic reviews of obesity intervention economic evaluations. Databases were searched for studies published between 2008 and 2013. For each study, we reviewed details of the model type, structure, and methods for predicting diabetes and cardiovascular disease. Our review identified 46 articles and found variation in modelling approaches for cost-effectiveness evaluations for the prevention of type 2 diabetes. Investigation of the variables used to estimate the risk of type 2 diabetes suggested that impaired glucose regulation, and body mass index were used as the primary risk factors for type 2 diabetes. A minority of cost-effectiveness models for diabetes prevention accounted for the multivariate impacts of interventions on risk factors for type 2 diabetes. Twenty-eight cost-effectiveness models included cardiovascular events in addition to type 2 diabetes. Few cost-effectiveness models have flexibility to evaluate different intervention types. We conclude that to compare a range of prevention interventions it is necessary to incorporate multiple risk factors for diabetes, diabetes-related complications and obesity-related co-morbidity outcomes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRef
2.
3.
Gray LJ, Davies MJ, Hiles S, Taub NA, Webb DR, Srinivasan BT, et al. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. Diabetologia. 2012;55(4):959–66.PubMedCrossRef
4.
5.
6.
Gillett M, Royle P, Snaith A, Scotland G, Poobalan A, Imamura M, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess. 2012;16(33):1–iv.
7.
Lehnert T, Sonntag D, Konnopka A, Riedel-Heller S, Konig HH. The long-term cost-effectiveness of obesity prevention interventions: systematic literature review. Obes Rev. 2012;13(6):537–53.PubMedCrossRef
8.
Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):iii–xi, 1.
9.
Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19(3):350–64.PubMedCrossRef
10.
Squires H. A methodological framework for developing the structure of public health economic models. PhD Thesis. UK: University of Sheffield; 2014.
11.
Griffiths UK, Anigbogu B, Nanchahal K. Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts. Appl Health Econ Health Policy. 2012;10(3):145–62.PubMedCrossRef
12.
13.
14.
Ara R, Brennan A. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries. Obes Rev. 2007;8(4):363–71.PubMedCrossRef
15.
Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making. 2004;24(1):9–19.PubMedCrossRef
16.
Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006;29(6):1237–41.PubMedCrossRef
17.
Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.PubMedCentralPubMedCrossRef
18.
19.
20.
Bertram MY, Lim SS, Barendregt JJ, Vos T, Bertram MY, Lim SS, et al. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53(5):875–81.PubMedCrossRef
21.
Caro JJ, Getsios D, Caro I, Klittich WS, O’Brien JA. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med. 2004;21(11):1229–36.PubMedCrossRef
22.
Colagiuri S, Walker AE, Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Affairs. 2008;27(1):256–68.PubMedCrossRef
23.
Dalziel K, Segal L, Dalziel K, Segal L. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions (review) (54 refs). Health Promot Int. 2007;22(4):271–83.PubMedCrossRef
24.
Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336(7654):1180–5.PubMedCentralPubMedCrossRef
25.
Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care. 2007;30(11):2874–9.PubMedCrossRef
26.
Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, et al. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a ‘real world’ routine healthcare setting: model based on the KORA Survey 2000. Diabetic Med. 2007;24(5):473–80.PubMedCrossRef
27.
Lindgren P, Lindstrom J, Tuomilehto J, Uusitupa M, Peltonen M, Jonsson B, et al. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007;23(2):177–83.PubMedCrossRef
28.
Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26(2):304–21.PubMedCrossRef
29.
Palmer AJ, Tucker DM, Palmer AJ, Tucker DMD. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Primary Care Diabetes. 2012;6(2):109–21.PubMedCrossRef
30.
Schaufler TM, Wolff M, Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8(3):191–202.PubMedCrossRef
31.
Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int. 1998;13(3):197–209.CrossRef
32.
Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, et al. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007. Prevent Chronic Dis. 2010;7(5):A109.
33.
Sullivan SD, Garrison LP Jr, Rinde H, Kolberg J, Moler EJ, Sullivan SD, et al. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ. 2011;14(5):609–16.PubMedCrossRef
34.
Zhuo X, Zhang P, Selvin E, Hoerger TJ, Ackermann RT, Li R, et al. Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. Am J Prevent Med. 2012;42(4):374–81.CrossRef
35.
Clegg A, Colquitt J, Sidhu M, Royle P, Walker A. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. Int J Obes Relat Metab Disord. 2003;27(10):1167–77.PubMedCrossRef
36.
Galani C, Schneider H, Rutten FF, Galani C, Schneider H, Rutten FFH. Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health. 2007;52(6):372–82.PubMedCrossRef
37.
38.
Hampp C, Hartzema AG, Kauf TL. Cost-utility analysis of rimonabant in the treatment of obesity. Value Health. 2008;11(3):389–99.PubMedCrossRef
39.
Hertzman P. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics. 2005;23(10):1007–20.PubMedCrossRef
40.
Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian obese patients. Curr Med Res Opin. 2008;24(1):63–74.PubMedCrossRef
41.
Lacey LA, Wolf A, O’Shea D, Erny S, Ruof J. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond). 2005;29(8):975–82.CrossRef
42.
43.
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13(41):1–357, iii.
44.
Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight loss interventions in overweight and obese women. Obesity (Silver Spring). 2006;14(6):1093–106.CrossRef
45.
Trueman P, Haynes SM, Felicity LG, Louise ME, McQuigg MS, Mongia S, et al. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract. 2010;64(6):775–83.PubMedCrossRef
46.
Forster M, Veerman JL, Barendregt JJ, Vos T, Forster M, Veerman JL, et al. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obesity. 2011;35(8):1071–8.CrossRef
47.
Sacks G, Veerman JL, Moodie M, Swinburn B, Sacks G, Veerman JL, et al. ‘Traffic-light’ nutrition labelling and ‘junk-food’ tax: a modelled comparison of cost-effectiveness for obesity prevention. Int J Obesity. 2011;35(7):1001–9.CrossRef
48.
Veerman JL, Barendregt JJ, Forster M, Vos T, Veerman JL, Barendregt JJ, et al. Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS ONE. 2011;6(10):e26051.PubMedCentralPubMedCrossRef
49.
Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med. 2009;6(7):e1000110.PubMedCentralPubMedCrossRef
50.
Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynaecol Obstet. 2011;115(Suppl 1):S20–5. doi:10.​1016/​S0020-7292(11)60007-6.​):​-6.PubMedCrossRef
51.
Roux L, Pratt M, Tengs TO, Yore MM, Yanagawa TL, Van Den Bos J, et al. Cost effectiveness of community-based physical activity interventions. Am J Prev Med. 2008;35(6):578–88.PubMedCrossRef
52.
Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P, et al. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care. 2009;25(3):350–8.PubMedCrossRef
53.
Van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM, Van Baal PHM, et al. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health. 2008;11(7):1033–40.PubMedCrossRef
54.
Cobiac L, Vos T, Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Aust N Z J Public Health. 2010;34(3):240–7.PubMedCrossRef
55.
Caro J, Stillman IO. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ. 2007;10:239–64.CrossRef
56.
Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA, et al. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care. 2007;30(1):128–134.
57.
Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84.PubMedCrossRef
58.
Feenstra TL, van Baal PM, Jacobs-van der Bruggen MO, Hoogenveen RT, Kommer GJ, Baan CA. Targeted versus universal prevention: a resource allocation model to prioritize cardiovascular prevention. Cost Eff Resour Alloc. 2011;9(1):14–19.
59.
Bemelmans W, van BP, Wendel-Vos W, Schuit J, Feskens E, Ament A, et al. The costs, effects and cost-effectiveness of counteracting overweight on a population level: a scientific base for policy targets for the Dutch national plan for action. Prevent Med. 2008;46(2):127–32.
60.
Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems: the mathematical formulation. J Biomed Inform. 2002;35(1):37–50.PubMedCrossRef
61.
Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136(8):575–81.PubMedCrossRef
62.
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83(1):356–62.PubMedCrossRef
63.
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33(7):1776–81.PubMedCrossRef
64.
Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671–9.CrossRef
65.
Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143(4):251–64.PubMedCrossRef
66.
van den Berg E, Biessels GJ, Stehouwer CD, Kappelle LJ, Heine RJ, Nijpels G, et al. Ten-year time course of risk factors for increased carotid intima-media thickness: the Hoorn Study. Eur J Cardiovasc Prev Rehabil. 2010;17(2):168–74.PubMedCrossRef
67.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRef
68.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.PubMedCrossRef
69.
Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581–6.PubMedCrossRef
70.
de VF, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285(16):2109–13.
71.
The Atherosclerosis Risk in Communities. (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687–702.
72.
Nakagami T, Tajima N, Oizumi T, Karasawa S, Wada K, Kameda W, et al. Hemoglobin A1c in predicting progression to diabetes. Diabetes Res Clin Pract. 2010;87(1):126–31.PubMedCrossRef
73.
Dahlgren G, Whitehead M. Policies and strategies to promote social equity in health. Stockholm: Institute for Future Studies; 1991.
74.
Johansen NB, Hansen AL, Mygind JT, Philipsen A, Rasmussen SS, Jorgensen ME, et al. Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health. 2012;12(1):1078.PubMedCentralPubMedCrossRef
75.
Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia. 1991;34(12):891–8.PubMedCrossRef
76.
Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension. 2000;36(1):20–5.PubMedCrossRef
77.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–7.PubMedCrossRef
78.
Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):136–45.PubMedCrossRef
79.
Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–6.PubMedCrossRef
80.
Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–84.PubMedCrossRef
81.
Gorsky RD, Pamuk E, Williamson DF, Shaffer PA, Koplan JP. The 25-year health care costs of women who remain overweight after 40 years of age. Am J Prev Med. 1996;12(5):388–94.PubMed
82.
Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999;42(7):793–801.PubMedCrossRef
83.
Hoogenveen R, Gijsen R, van Genugten MLL, Kommer GJ, Schouten JSAG, de Hollander AEM. Constructing a set of consistent data for chronic disease modelling. Bilthoven: National Institute of Public Health and the Environment (RIVM); 2000.
84.
ABS National Health Survey 2001. Summary of results, Cat no. 4364.0. Canberra: ABS 2002; 2002.
85.
ABS, National Health Survey 2004-5. Summary of results, Cat no. 4364.0. Canberra: ABS, 2006; 2006.
86.
Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–7.PubMedCrossRef
87.
Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Comm Health. 2005;59(2):134–9.CrossRef
88.
Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280(21):1843–8.PubMedCrossRef
89.
Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord. 2001;25(7):1047–56.PubMedCrossRef
90.
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef
91.
92.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef
93.
Wolfe CD, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72(2):211–6.PubMedCentralPubMedCrossRef
94.
Ni MC, Parag V, Nakamura M, Patel A, Rodgers A, Lam TH. Body mass index and risk of diabetes mellitus in the Asia-Pacific region. Asia Pac J Clin Nutr. 2006;15(2):127–33.
95.
Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Court et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab): methods and response rates. Diabetes Res Clin Pract. 2002;57(2):119–29.
96.
Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1(1):4.PubMedCentralPubMedCrossRef
97.
Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46(2):182–9.PubMed
98.
Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany: results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110(1):10–6.PubMedCrossRef
99.
Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113(25):2914–8.PubMedCrossRef
100.
Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004;27(12):2806–12.PubMedCrossRef
101.
Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327(7426):1267.PubMedCentralPubMedCrossRef
102.
Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–9.PubMedCentralPubMedCrossRef
103.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.PubMedCentralPubMedCrossRef
104.
Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009;32(7):1207–12.PubMedCentralPubMedCrossRef
105.
Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86.PubMedCrossRef
106.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837–853.
Metadaten
Titel
Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods
verfasst von
P. Watson
L. Preston
H. Squires
J. Chilcott
A. Brennan
Publikationsdatum
01.06.2014
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 3/2014
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-014-0091-z

Weitere Artikel der Ausgabe 3/2014

Applied Health Economics and Health Policy 3/2014 Zur Ausgabe

Systematic Review

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Original Research Article

Healthcare Use and Voluntary Health Insurance After Retirement in Thailand

Original Research Article

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis

Original Research Article

Paying for Formerly Free Medicines in Spain After 1 Year of Co-Payment: Changes in the Number of Dispensed Prescriptions

Original Research Article

Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development

Review Article

Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers